Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Novel immune checkpoint blockade with ipilimumab, an antibody blocking the cytotoxic T-lymphocyte antigen 4 (CTLA4), is revolutionizing cancer therapy. However, ipilimumab induces symptomatic, sometimes severe, endocrine immune-related adverse events (irAEs) that are inconsistently recognized and reported. The objective of this review was to comprehensively characterize the incidence, presentation, and management of endocrinopathies following ipilimumab therapy in a single center that is highly specialized in immune checkpoint blockade. We carried out a retrospective analysis of endocrine irAEs in melanoma patients receiving ipilimumab therapy in clinical trials between 2007 and 2013. A total of 256 patients were included in this analysis. We reviewed pituitary-, thyroid-, and adrenal-related hormone test results, as well as radiographic studies and the clinical histories of patients, to identify and characterize cases of hypophysitis, hypothyroidism, thyroiditis, and adrenal dysfunction. Following ipilimumab therapy, the overall incidence of hypophysitis was 8% and that of hypothyroidism/thyroiditis 6%. Primary adrenal dysfunction was rare. Therapy with a combination of ipilimumab and nivolumab, an anti-programmed cell death 1 (PDCD1, also called PD1) receptor antibody, was associated with a 22% incidence of either thyroiditis or hypothyroidism and a 9% incidence of hypophysitis. Symptomatic relief, in particular, for hypophysitis, was achieved in all patients with hormone replacement, although endogenous hormone secretion rarely recovered. In summary, we observed that CTLA4 blockade alone, and in particular in combination with PD1 blockade, is associated with an increased risk of symptomatic, sometimes severe, hypophysitis as well as thyroid dysfunction. Prompt initiation with hormone replacement reverses symptoms. Evaluation and reporting of endocrine irAEs in clinical trials should be done using standardized diagnostic criteria and terminology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“novel biological drugs inducing hypophysitis such as ipilimumab or other check-point inhibitors (63).”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [46]
Experimental — accuracy not yet measuredIn the citing paper
“the rexinoids (e.g. bexarotene), directly repressing TSHβ expression”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
In the citing paper
“mitotane, which decreases viability of thyrotrope cells”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The higher overall incidence of hypophysitis in the studies (8%) reviewed compared with that in most of the published trials probably reflects our welldefined clinical, biochemical, and radiographic criteria for identifying cases, which is highly inconsistent and ambiguous in published clinical trials (Hodi et al. 201…”
BackgroundResultInfluentialSelf-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Nivolumab, a second antibody-derived immune regulator, blocks the activation of the anti-programmed cell death 1 (PDCD1, also called PD1) receptor (Topalian et al. 2012).”
BackgroundAssociation of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175 · cited 2×
“…pituitary hormone secretion. http://erc.endocrinology-journals.org q 2014 Society for Endocrinology DOI: 10.1530/ERC-13-0499 Printed in Great Britain There is a clear association betweenCTLA4 and sporadic, autoimmune thyroid disease in humans and mice (Tomer et al. 2001, Ueda et al. 2003).”
BackgroundInfluentialCTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940 · cited 1×
“The engagement of CTLA4 by its ligands in the B7 co-stimulatory family suppresses T-cell proliferation, helping restore tissue homeostasis (Egen et al. 2002, Pentcheva-Hoang et al. 2004).”
BackgroundCaturegli, P., Newschaffer, C., Olivi, A., Pomper, M. G., Burger, P. C., & Rose, N. R. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0011 · Cited by 588
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 570
B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse
Pentcheva-Hoang, T., Egen, J. G., Wojnoonski, K., & Allison, J. P. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.017 · Cited by 436
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
Dillard, T., Yedinak, C. G., Alumkal, J., & Fleseriu, M. (2010) · Pituitary · doi:10.1007/s11102-009-0193-z · Cited by 300
Research works printed but not linked: 1
- 2005, 28, 593
Cited by
Items 101–200 of 460
The diagnosis and management of central hypothyroidism in 2018
Persani, L., Cangiano, B., & Bonomi, M. (2019) · Endocrine Connections · doi:10.1530/ec-18-0515 · Cited by 64
Advanced Renal Cell Carcinoma: Role of the Radiologist in the Era of Precision Medicine
Shinagare, A. B., Krajewski, K. M., Braschi‐Amirfarzan, M., & Ramaiya, N. H. (2017) · Radiology · doi:10.1148/radiol.2017160343 · Cited by 64
Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist
Lewis, A., Chaft, J. E., Girotra, M., & Fischer, G. W. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.11.034 · Cited by 64
Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT
Wachsmann, J. W., Ganti, R., & Peng, F. (2017) · Academic Radiology · doi:10.1016/j.acra.2016.08.005 · Cited by 63
Kassi, E. N., Angelousi, A. G., Asonitis, N., Diamantopoulos, P. T., Anastasopoulou, A. N., Papaxoinis, G., Kokkinos, M., Giovannopoulos, I., Kyriakakis, G., Petychaki, F., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2533 · Cited by 63
Nagai, H., & Muto, M. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1259-6 · Cited by 61
Russell, R. R., Alexander, J. S., Jain, D., Poornima, I. G., Srivastava, A. V., Storozynsky, E., & Schwartz, R. G. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-016-0538-8 · Cited by 61
Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab
Kitajima, K., Ashida, K., Wada, N. A., Suetsugu, R., Takeichi, Y., Sakamoto, S., Uchi, H., Matsushima, T., Shiratsuchi, M., Ohnaka, K., et al. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx018 · Cited by 60
Novel therapeutic strategies for spinal osteosarcomas
Anwar, M. A., El‐Baba, C., Elnaggar, M. H., Elkholy, Y. O., Mottawea, M., Johar, D., Shehabi, T. S. A., Kobeissy, F. H., Moussalem, C. K., Massaad, E., et al. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.018 · Cited by 60
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns
Nguyen, H. T., Shah, K. B., Waguespack, S. G., Hu, M. I.-N., Habra, M. A., Cabanillas, M. E., Busaidy, N. L., Bassett, R. L., Zhou, S., Iyer, P. C., et al. (2021) · Endocrine Related Cancer · doi:10.1530/erc-20-0513 · Cited by 60
Checkpoint inhibitors in AML: are we there yet?
Ghosh, A., Barba, P., & Perales, M. (2019) · British Journal of Haematology · doi:10.1111/bjh.16358 · Cited by 60
Treatment of Ipilimumab Induced Graves’ Disease in a Patient with Metastatic Melanoma
Azmat, U., Liebner, D., Joehlin-Price, A., Agrawal, A., & Nabhan, F. (2016) · Case Reports in Endocrinology · doi:10.1155/2016/2087525 · Cited by 59
Tremelimumab-Induced Graves Hyperthyroidism
Gan, E. H., Mitchell, A. L., Plummer, R., Pearce, S., & Perros, P. (2017) · European Thyroid Journal · doi:10.1159/000464285 · Cited by 58
The Changing Clinical Spectrum of Hypophysitis
Chiloiro, S., Capoluongo, E., Tartaglione, T., Giampietro, A., Bianchi, A., Giustina, A., Pontecorvi, A., & Marinis, L. D. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.06.004 · Cited by 58
Anticancer Drug-induced Thyroid Dysfunction
Bhattacharya, S., Goyal, A., Kaur, P., Medanta, T. M., Singh, R. K., & Kalra, S. (2020) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2020.16.1.32 · Cited by 58
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Rahman, M. M., Behl, T., Islam, M. R., Alam, M. N. A., Islam, M. M., Albarrati, A., Albratty, M., Meraya, A. M., & BUNGAU, S. G. (2022) · Molecules · doi:10.3390/molecules27123798 · Cited by 57
Salama, A. K. S., & Moschos, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw534 · Cited by 57
Thyroid eye disease: what is new to know?
Li, Z., Cestari, D. M., & Fortin, É. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000529 · Cited by 56
Özdemir, B. C. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002220 · Cited by 56
Management of immune related adverse events induced by immune checkpoint inhibition
Teufel, A., Zhan, T., Härtel, N., Bornschein, J., Ebert, M. P., & Schulte, N. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.018 · Cited by 56
Immune checkpoint inhibitors-related orchitis
Brunet‐Possenti, F., Opsomer, M.-A., Gómez, L. A., Ouzaïd, I., & Descamps, V. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw696 · Cited by 56
Kottschade, L. A. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0671-4 · Cited by 54
Sakurai, K., Niitsuma, S., Sato, R., Takahashi, K., & Arihara, Z. (2018) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.244.33 · Cited by 52
Gunawan, F., George, E., & Roberts, A. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-17-0146 · Cited by 52
Johnson, J. N., Goldner, W. S., Abdallah, D., Qiu, F., Ganti, A. K., & Kotwal, A. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7098 · Cited by 52
A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
Qu, J., Wang, L., Jiang, M., Zhao, D., Wang, Y., Zhang, F., Li, J., & Zhang, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s257188 · Cited by 52
Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer
(2018) · In Vivo · doi:10.21873/invivo.11166 · Cited by 51
Atezolizumab for the treatment of non-small cell lung cancer
Santini, F. C., & Rudin, C. M. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1356717 · Cited by 51
Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy
Uppal, N. N., Workeneh, B., Rondon‐Berrios, H., & Jhaveri, K. D. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14671121 · Cited by 49
Autoimmune Thyroiditis and Myasthenia Gravis
Lopomo, A., & Berrih‐Aknin, S. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00169 · Cited by 49
Immune Checkpoint Inhibitor-Induced Hypophysitis: Lessons Learnt from a Large Cancer Cohort
Kotwal, A., Rouleau, S. G., Dasari, S., Kottschade, L. A., Ryder, M. M., Kudva, Y. C., Markovic, S. N., & Erickson, D. Z. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002099 · Cited by 48
Self-citationBrilli, L., Danielli, R., Ciuoli, C., Calabrò, L., Giacomo, A. M. D., Cerase, A., Paffetti, P., Sestini, F., Porcelli, B., Maio, M., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1289-2 · Cited by 48
Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00311 · Cited by 48
Pituitary Medicine From Discovery to Patient-Focused Outcomes
Melmed, S. K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3653 · Cited by 47
Clinical Update in Aspects of the Management of Autoimmune Thyroid Diseases
Topliss, D. J. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.4.493 · Cited by 47
Nivolumab-induced thyroid dysfunction
Tanaka, R., Fujisawa, Y., Maruyama, H., Nakamura, Y., Yoshino, K., Ohtsuka, M., & Fujimoto, M. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw036 · Cited by 47
Immune-related adverse events by immune checkpoint inhibitors
Kadono, T. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.83 · Cited by 47
Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More
Ellithi, M., Elnair, R. A., Chang, G. V., & Abdallah, M. A. (2020) · Cureus · doi:10.7759/cureus.6935 · Cited by 47
Yuen, K. C. J., Samson, S. L., Bancos, I., Gosmanov, A. R., Jasim, S., Fecher, L. A., & Weber, J. S. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.04.010 · Cited by 46
Levy, M., Abeillon, J., Dalle, S., Assaad, S., Borson‐Chazot, F., Disse, E., Raverot, G., & Cugnet‐Anceau, C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103280 · Cited by 46
Roberts, K., Culleton, V., Lwin, Z., O'Byrne, K., & Hughes, B. G. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12698 · Cited by 46
Khosroshahi, L. M., Parhizkar, F., Kachalaki, S., Aghebati‐Maleki, A., & Maleki, L. A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107935 · Cited by 46
Immunotherapy for non-small cell lung cancer: current concepts and clinical trials
Mayor, M., Yang, N., Sterman, D. H., Jones, D. R., & Adusumilli, P. S. (2015) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezv371 · Cited by 46
Illouz, F., Briet, C., Cloix, L., Corre, Y. L., Baize, N., Urban, T., Martin, L., & Rodien, P. (2017) · Cancer Medicine · doi:10.1002/cam4.1145 · Cited by 45
Novel cancer therapies and their association with diabetes
Shariff, A. I., Syed, S. H., Shelby, R. A., Force, J. M., Clarke, J. M., D’Alessio, D. A., & Corsino, L. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0002 · Cited by 44
Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies
Tsoli, M., Kaltsas, G., Angelousi, A. G., Alexandraki, K., Randeva, H. S., & Kassi, E. N. (2020) · Cancer Management and Research · doi:10.2147/cmar.s224791 · Cited by 43
Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
Singh, V., Khurana, A., Allawadhi, P., Banothu, A. K., Bharani, K. K., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.790963 · Cited by 43
A Review of Immune-Mediated Adverse Events in Melanoma
Kennedy, L. B., & Salama, A. K. S. (2019) · Oncology and Therapy · doi:10.1007/s40487-019-0096-8 · Cited by 43
Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism
Lupi, I., Brancatella, A., Cetani, F., Latrofa, F., Kemp, E. H., & Marcocci, C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa092 · Cited by 43
Sattar, S., Haase, K. R., Bradley, C., Papadopoulos, E., Kuster, S., Mina, D. S., Tippe, M., Kaur, A., Campbell, D., Joshua, A. M., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00399-0 · Cited by 42
Alessandrino, F., Sahu, S., Nishino, M., Adeni, A. E., Tirumani, S. H., Shinagare, A. B., & Awad, M. M. (2019) · Abdominal Radiology · doi:10.1007/s00261-019-01935-2 · Cited by 42
Mogamulizumab for the treatment of T-cell lymphoma
Makita, S., & Tobinai, K. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1347634 · Cited by 42
Immune checkpoint inhibitor-related hypophysitis
Mizukoshi, T., Fukuoka, H., & Takahashi, Y. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101668 · Cited by 41
Testosterone deficiency in men receiving immunotherapy for malignant melanoma
Peters, M., Pearlman, A. M., Terry, W. W., Mott, S. L., & Monga, V. (2021) · Oncotarget · doi:10.18632/oncotarget.27876 · Cited by 40
Hughes, T. M., Klairmont, M. M., Sharfman, W. H., & Kaufman, H. L. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1095401 · Cited by 40
Shang, Y. H., Zhang, Y., Li, J. H., Li, P., & Zhang, X. (2017) · Immunotherapy · doi:10.2217/imt-2016-0147 · Cited by 39
Melmed, S. K., & Kleinberg, D. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00009-5 · Cited by 39
Lupu, J., Pages, C., Laly, P., Delyon, J., Laloi, M., Petit, A., Basset-Seguin, N., Oueslati, I., Zagdanski, A.-M., Young, J., et al. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000405 · Cited by 38
Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
Valecha, G. K., Vennepureddy, A., Ibrahim, U., Safa, F., Samra, B., & Atallah, J. P. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1259574 · Cited by 38
Bai, X., Chen, X., Wu, X., Huang, Y., Zhuang, Y., & Lin, X. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0535 · Cited by 38
Ipilimumab‐induced hypophysitis in melanoma patients: an Australian case series
Lam, T., Chan, M. M. K., Sweeting, A. N., De Sousa, S. M. C., Clements, A., Carlino, M. S., Long, G. V., Tonks, K., Chua, E., Kefford, R. F., et al. (2015) · Internal Medicine Journal · doi:10.1111/imj.12819 · Cited by 37
Cooksley, T., Girotra, M., Ginex, P., Gordon, R. A., Anderson, R., Blidner, A. G., Choi, J. N., Dougan, M. L., Glezerman, I. G., Gupta, D., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05709-1 · Cited by 37
Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis
Sousa, S. M. C. D., Sheriff, N., Tran, C. H., Menzies, A. M., Tsang, V., Long, G. V., & Tonks, K. T. T. (2018) · Pituitary · doi:10.1007/s11102-018-0866-6 · Cited by 36
Immune checkpoint inhibitor–associated hypercalcaemia
Izzedine, H., Chazal, T., Wanchoo, R., & Jhaveri, K. D. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa326 · Cited by 35
Checkpoint inhibition and melanoma: Considerations in treating the older adult
Friedman, C. F., & Wolchok, J. D. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.04.003 · Cited by 35
Self-citationEndocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy
Atkinson, M. A., & Lansdown, A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101635 · Cited by 35
Okiyama, N., & Tanaka, R. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.95 · Cited by 34
Pozzessere, C., Mazini, B., Omoumi, P., Jreige, M., Noirez, L., Digklia, A., Fasquelle, F., Sempoux, C. L., & Dromain, C. (2024) · Cancers · doi:10.3390/cancers16142585 · Cited by 34
Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J. (2021) · Cancers · doi:10.3390/cancers13081944 · Cited by 33
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
BackgroundLabadzhyan, A., Wentzel, K. P., Hamid, O., Chow, K., Kim, S., Piro, L. D., & Melmed, S. K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac161 · Cited by 33
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
Okura, N., Asano, M., Uchino, J., Morimoto, Y., Iwasaku, M., Kaneko, Y., Yamada, T., Fukui, M., & Takayama, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072033 · Cited by 33
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy
Chiloiro, S., Bianchi, A., Giampietro, A., Milardi, D., Marinis, L. D., & Pontecorvi, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.10.009 · Cited by 33
MacDonald, L., Jenkins, J., Purvis, G., Lee, J. Y., & Franco, A. T. (2020) · Hormones and Cancer · doi:10.1007/s12672-020-00390-6 · Cited by 33
Endocrinopathies with use of cancer immunotherapies
Villa, N. M., Farahmand, A., Du, L., Yeh, M. W., Praw, S. S., Ribas, A., Chmielowski, B., Cherry, G., & Leung, A. M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13483 · Cited by 32
Endocrine sequelae of immune checkpoint inhibitors
Ntali, G., Kassi, E. N., & Alevizaki, M. K. (2017) · HORMONES · doi:10.14310/horm.2002.1754 · Cited by 32
Expert opinion on pituitary complications in immunotherapy
Briet, C., Albarel, F., Kuhn, E., Merlen, E., Chanson, P., & Cortet, C. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.008 · Cited by 32
Yeung, S. J., Qdaisat, A. Z., Chaftari, P. S., Lipe, D. N., Merlin, J., Rajha, E., Wechsler, A. H., Sandoval, M., Viets-Upchurch, J. M., Al‐Breiki, A., et al. (2020) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12209 · Cited by 32
Mori, S., Kurimoto, T., Ueda, K., Enomoto, H., Sakamoto, M., Keshi, Y., Yamada, Y., & Nakamura, M. (2018) · Case Reports in Ophthalmology · doi:10.1159/000491075 · Cited by 32
Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy
Deligiorgi, M. V., Siasos, G., Vergadis, C., & Trafalis, D. T. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106427 · Cited by 31
Knight, T., Ahn, S., Rice, T. W., & Cooksley, T. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.09.025 · Cited by 31
Meybodi, S. M., Far, B. F., Pourmolaei, A., Baradarbarjastehbaf, F., Safaei, M., Mohammadkhani, N., & Samadani, A. A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02114-6 · Cited by 31
Polysaccharides from marine resources exhibit great potential in the treatment of tumor: A review
Ju, H., Yu, C. H. A., Liu, W., Li, H., Fu, Z. Q., Wu, Y., Gong, P., & Li, H.-J. (2023) · Carbohydrate Polymer Technologies and Applications · doi:10.1016/j.carpta.2023.100308 · Cited by 31
Yuen, K. C. J., POPOVIC, V. M., & Trainer, P. J. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.04.010 · Cited by 30
Inflammatory and Infectious Disorders in Endocrine Pathology
Uccella, S., Dottermusch, M., Erickson, L. A., Warmbier, J., Montone, K. T., & Saeger, W. (2023) · Endocrine Pathology · doi:10.1007/s12022-023-09771-3 · Cited by 30
Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis
Cosci, I., Grande, G., Nisio, A. D., Rocca, M. S., Fiore, P. D., Benna, C., Mocellin, S., & Ferlin, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010599 · Cited by 30
The Future of Immunotherapy in the Treatment of Cancer
Kottschade, L. A. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.08.013 · Cited by 29
Simmons, D., & Lang, E. (2017) · Cureus · doi:10.7759/cureus.1774 · Cited by 28
Immunotherapy in Metastatic Melanoma: A Novel Scenario of new Toxicities and their Management
Simeone, E., Grimaldi, A. M., Festino, L., Trojaniello, C., Vitale, M. G., Vanella, V., Palla, M., & Ascierto, P. A. (2019) · Melanoma Management · doi:10.2217/mmt-2019-0005 · Cited by 28
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128_g · Cited by 28
New Molecular, Biological, and Immunological Agents Inducing Hypophysitis
Angelousi, A. G., Chatzellis, E., & Kaltsas, G. (2017) · Neuroendocrinology · doi:10.1159/000480086 · Cited by 28
Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?
Percik, R., & Shoenfeld, Y. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101411 · Cited by 27
Queirolo, P., Dozin, B., Morabito, A., Banelli, B., Carosio, R., Fontana, V., Ferrucci, P. F., Martinoli, C., Cocorocchio, E., Ascierto, P. A., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.04.005 · Cited by 27
Kastrisiou, M., Kostadima, F.-L., Kefas, A., Zarkavelis, G., Kapodistrias, N., Ntouvelis, E., Petrakis, D., Papadaki, A., Vassou, A., & Pentheroudakis, G. E. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000217 · Cited by 27
Multimodality imaging of endocrine immune related adverse events: a primer for radiologists
Alessandrino, F., Shah, H., & Ramaiya, N. H. (2018) · Clinical Imaging · doi:10.1016/j.clinimag.2017.12.014 · Cited by 27
Endocrine toxicity of cancer immunotherapy: clinical challenges
Anderson, B., & Morganstein, D. L. (2021) · Endocrine Connections · doi:10.1530/ec-20-0489 · Cited by 27
Immune checkpoint inhibitors and endocrine side effects, a narrative review
Agrawal, L., Bacal, A., Jain, S., Singh, V., Emanuele, N. V., Emanuele, M. A., & Meah, F. A. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2019.1709344 · Cited by 27
Manaka, K., Sato, J., Takeuchi, M., Watanabe, K., Kage, H., Kawai, T., Sato, Y., Miyagawa, T., Yamada, D., Kume, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91032-6 · Cited by 27
Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer
Rossi, E., Sgambato, A., Chiara, G. D., Casaluce, F., Losanno, T., Sacco, P. C., Santabarbara, G., & Gridelli, C. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1133289 · Cited by 26
Minding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology
Kim, A. E., Nelson, A. A., Stimpert, K., Flyckt, R. L., Thirumavalavan, N., Baker, K., Weinmann, S. C., & Hoimes, C. J. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00469 · Cited by 26
A Novel Etiology of Hypophysitis
Fernandes, S., Varlamov, E. V., McCartney, S., & Fleseriu, M. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.05.002 · Cited by 25
Metadata
- Authors
- Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A.
- Affiliations
- Mayo Clinic (US)
- Weill Cornell Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Ryder, Mabel
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2014-04
- Volume
- 21
- Issue
- 2
- Pages
- 371-381
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- PMC
- PMC4573438
- OpenAlex
- W2166107256
- Cited by
- 439
- References
- 14
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 23 · 2023: 21 · 2022: 32 · 2021: 44 · 2020: 49 · 2019: 55 · 2018: 53 · 2017: 56 · 2016: 44 · 2015: 25 · 2014: 5
- FWCI
- 20.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- GlaxoSmithKline
- National Cancer Institute (K08CA133183, P50CA172012, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- ipilimumab, immune-related adverse events, CTLA-4 blockade, immune checkpoint inhibitors, advanced melanoma, hypophysitis, hypothyroidism, thyroiditis, adrenal dysfunction, nivolumab, anti-PD-1 therapy, hormone replacement therapy, endocrine toxicity
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Antineoplastic Agents, Endocrine System Diseases, Humans, Melanoma, Skin Neoplasms, Testosterone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.